GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy

E-ISSN： 1996-3181|10|6|703-711

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.10, Iss.6, 2011-09, pp. : 703-711

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gene Therapy for Parkinson's Disease: Current Status and Future Potential

By Segovia J.

American Journal of PharmacoGenomics, Vol. 2, Iss. 2, 2002-01 ,pp. : 135-146

Adis International

Access to resources Recommend Favorite

GDNF gene therapy: potent benefits in Parkinson's disease?

Inpharma, Vol. 1, Iss. 1266, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Potential Influences of Complementary Therapy on Motor and Non-Motor Complications in Parkinson's Disease

By Zesiewicz Theresa A.

CNS Drugs, Vol. 23, Iss. 10, 2009-10 ,pp. : 817-835

Adis International

Access to resources Recommend Favorite

3,4-Dihydroxyphenylacetaldehyde: A Potential Target for Neuroprotective Therapy in Parkinson's Disease

Current Drug Targets-CNS & Neurological Disorders, Vol. 2, Iss. 2, 2003-04 ,pp. : 143-148

Bentham Science Publishers

Access to resources Recommend Favorite

Angiotensin ATReceptor Ligands: Do They Have Potential as Future Treatments for Neurological Disease?

By Rosenstiel P.

CNS Drugs, Vol. 16, Iss. 3, 2002-01 ,pp. : 145-153

Adis International

Access to resources Recommend Favorite